More USFDA approvals do not mean better margins for Indian 'big pharma'

Indian pharma firms including their subsidiaries have received around 304 abbreviated new drug application approvals from the USFDA in 2017

The pace of US Food and Drug Administration (USFDA) approvals has picked up, but that has not necessarily converted into better profit margins for 'big pharma' in India. In fact, most big pharma firms have seen their margins shrink over the last three years barring a few such as Glenmark, which have seen a boost due to limited competition products. 

Indian pharma firms including their subsidiaries have received around 304 abbreviated new drug application (ANDA) approvals from the USFDA in 2017 (compared to 201 ANDA approvals in 2016). While this is expected to translate into higher revenues in the mid